NovoCure (NVCR) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12 month price objectives for NovoCure's stock. Their NVCR share price forecasts range from $25.00 to $102.00. On average, they predict the company's share price to reach $52.38 in the next twelve months. This suggests a possible upside of 224.3% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR stock has decreased by 78.0% and is now trading at $16.15.
View the best growth stocks for 2023 here.

NovoCure saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 7,580,000 shares, a decrease of 17.7% from the August 31st total of 9,210,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is presently 4.3 days. Approximately 7.9% of the company's shares are short sold.
View NovoCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, July, 27th. The medical equipment provider reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.04. The medical equipment provider earned $126.05 million during the quarter, compared to analysts' expectations of $124.25 million. NovoCure had a negative net margin of 34.35% and a negative trailing twelve-month return on equity of 40.21%. The firm's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.23) earnings per share.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco NASDAQ Next Gen 100 ETF (QQQJ), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCR stock can currently be purchased for approximately $16.15.

NovoCure (NASDAQ:NVCR) has a market capitalization of $1.72 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

The company employs 1,320 workers across the globe.

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.